DEFA14A: Neuronetics to Acquire Greenbrook TMS: Aims to Amplify Brand Awareness and Enhance Practice Support

Neuronetics is set to acquire Greenbrook TMS to leverage combined strengths, amplify brand awareness, and provide enhanced value to NeuroStar practices.

Summary

• Neuronetics, Inc. is acquiring Greenbrook TMS to enhance brand awareness and support NeuroStar practices.
• The acquisition aims to transform Greenbrook's 120 locations into NeuroStar centers, expanding the reach of NeuroStar's brand.
• The goal is to make NeuroStar a household name for patients battling depression, driving more patients to NeuroStar providers.
• The acquisition will provide NeuroStar practices with access to Greenbrook's back-office structure, including payer contracts and insurance billing services.
• A centralized call center will be available to NeuroStar practices, improving patient follow-up and reducing administrative burdens.
• Greenbrook's expertise in referral networks will be leveraged to help NeuroStar practices attract more patients.
• The combined entity will offer a broader range of services, including TMS, Spravato, and medication management.
• Neuronetics aims to achieve cash flow break-even in the fourth quarter of 2024 and on a full-year basis in 2025.
• The acquisition is expected to close by the end of 2024.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook on the acquisition, highlighting the potential benefits for Neuronetics, Greenbrook, and NeuroStar practices. The management's comments and the focus on growth and efficiency contribute to the positive sentiment.

Positives

• Amplified brand awareness for NeuroStar through the conversion of Greenbrook locations.
• Access to Greenbrook's established payer contracts and insurance billing services for NeuroStar practices.
• A centralized call center to improve patient follow-up and reduce administrative burdens.
• Leveraging Greenbrook's expertise in referral networks to attract more patients.
• Expanded service offerings including TMS, Spravato, and medication management.
• Potential for higher reimbursement rates through combined scale and negotiation power.
• Improved cash flow for NeuroStar practices through faster claims processing.
• Opportunity for NeuroStar practices to incorporate med management and Spravato into their offerings.
• The Better Me Provider program will be extended to Greenbrook locations.

Negatives

• Potential disruption during the integration of Greenbrook into Neuronetics.
• Risk of employee retention issues at Greenbrook following the acquisition.
• Possible decline in Greenbrook's and Neuronetics' stock prices if the transaction is not completed.
• The need to phase out the Greenbrook name, which may have some brand equity.
• Integration challenges in combining different practice management systems and cultures.

Risks

• The ability to meet expectations regarding the timing and completion of the acquisition.
• The occurrence of any event that would lead to the termination of the acquisition agreement.
• Failure of Greenbrook's and Neuronetics' stockholders to approve the acquisition.
• The disruption of management's attention from ongoing business operations due to the acquisition.
• The effect of the announcement on Greenbrook's and Neuronetics' relationships with their customers.
• The outcome of any legal proceedings related to the acquisition.
• Retention of Greenbrook employees following the announcement.
• Potential decline in Greenbrook's and Neuronetics' stock prices if the acquisition is not completed.
• The ability to achieve or sustain profitable operations due to Neuronetics' history of losses.
• Reliance on the sale and usage of the NeuroStar Advanced Therapy System to generate revenues.
• Availability of coverage and reimbursement from third-party payors for treatments using NeuroStar products.
• Physician and patient demand for treatments using NeuroStar products.
• Developments in competing technologies and therapies.
• Product defects.
• Concentration of revenue among a small number of customers.
• Ability to obtain and maintain intellectual property protection.
• Developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System.
• Developments in regulation in the U.S. and other applicable jurisdictions.
• Terms of Neuronetics' credit facility.
• Ability to successfully roll-out the Better Me Provider Program.
• Self-sustainability and existing cash balances.
• Ability to achieve cash flow break-even in the fourth quarter of 2024 and on a full-year basis in 2025.

Future Outlook

Neuronetics aims to amplify brand awareness, improve practice efficiency, and expand service offerings to drive growth and profitability.

Management Comments

• Keith Sullivan stated that the acquisition will help drive greater awareness and get to more patients.
• Bill Leonard mentioned that the combined team will share best practices and create access to services that Greenbrook has done well.
• Keith Sullivan believes that the purchase of Greenbrook will help drive awareness and educate patients more.

Industry Context

The acquisition reflects a trend towards consolidation in the TMS market, with companies seeking to expand their reach and offer a broader range of services to mental health providers.

Comparison to Industry Standards

• The acquisition of Greenbrook by Neuronetics is similar to how Starbucks built brand recognition through brick-and-mortar stores before expanding into other locations.
• Greenbrook's expansion into Spravato and Med Management mirrors the trend of TMS providers offering a wider range of mental health services.
• The goal of achieving higher reimbursement rates through scale is a common objective in the healthcare industry.
• The Better Me Provider program is similar to certification programs offered by other medical device companies to ensure quality of care.

Stakeholder Impact

• Shareholders of Neuronetics and Greenbrook will be asked to approve the acquisition.
• NeuroStar practices will benefit from increased brand awareness, access to new services, and improved reimbursement rates.
• Patients will have greater access to NeuroStar treatments and a broader range of mental health services.
• Employees of Greenbrook will be integrated into Neuronetics, with potential changes in roles and responsibilities.
• Suppliers and creditors of Neuronetics and Greenbrook may be affected by the acquisition, depending on the terms of the transaction.

Next Steps

• Finalize the acquisition of Greenbrook TMS by the end of 2024.
• Transform Greenbrook's 120 locations into NeuroStar centers.
• Integrate Greenbrook's back-office structure and service offerings into Neuronetics.
• Develop and implement a unified marketing strategy to promote the NeuroStar brand.
• Cross-train Neuronetics and Greenbrook teams on best practices and service offerings.
• Negotiate national and regional payer contracts to improve reimbursement rates.
• Expand the Better Me Provider Program to Greenbrook locations.
• Educate practices on how to incorporate med management and Spravato into their offerings.

Key Dates

Keywords

Neuronetics, Greenbrook TMS, Acquisition, TMS, NeuroStar, Mental Health, Depression, Spravato, Healthcare, Treatment